Anbio Biotechnology Stock
Anbio Biotechnology Class A Ordinary Shares
Company data
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Country
- Germany
- CEO
- Michael Lau
- Employees
- 27
- Market cap
- $137 M
- IPO
- 19/02/2025
Anbio Biotechnology Class A Ordinary Shares operates within the healthcare sector as a provider in the medical instruments and supplies industry. Established in 2021 and headquartered in Frankfurt am Main, Germany, the company is led by CEO Michael Lau. With 27 employees, the firm serves as a global supplier of in…
Company description based on the data provider's company data, AI-assisted, created on 15/10/2026. Not investment advice.
Anbio Biotechnology stock: price history
1D
-5.2%
1W
-32.8%
1M
-43.9%
6M
-88.5%
YTD
-89.6%
1Y
-88.7%
2Y
–
5Y
–
10Y
–
Anbio Biotechnology stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Anbio Biotechnology is a global provider of in vitro diagnostics that manufactures and distributes various testing solutions for the medical sector. Its product portfolio includes rapid tests for SARS-CoV-2 as well as Influenza A/B and utilizes technological methods such as lateral flow immunoassay and real-time PCR. The products are distributed through different channels, encompassing retail, point-of-care applications, and professional laboratories. Revenue is geographically distributed across various regions, with the European market and the Asia-Pacific region representing the largest segments.
- Revenue model
- Transactional
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Anbio Biotechnology
Anbio Biotechnology stock metrics
P/E
16.18
P/B
4.56
EV/EBITDA
20.01
RETURN ON EQUITY
10.1%
NET MARGIN
64.1%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
31/12/2025
Free float & liquidity
FREE FLOAT
90.4%
FLOAT SHARES
39,691,251
AVG. DAILY VOLUME (30D)
155,106
Institutional holders
Comparable stocks
Frequently asked questions about Anbio Biotechnology stock
What does Anbio Biotechnology do?
Anbio Biotechnology Class A Ordinary Shares is a company in the Healthcare sector, Medical - Instruments & Supplies industry, headquartered in Germany.
The CEO is Michael Lau, the company employs around 27 people.
The IPO was on 19/02/2025; the stock trades on NASDAQ under the ticker NNNN.
Does Anbio Biotechnology pay a dividend?
No, Anbio Biotechnology currently does not pay a dividend.
Which stocks are comparable to Anbio Biotechnology?
Comparable stocks include Sartorius, Intuitive Surgical, Becton, Dickinson and Company, ResMed, West Pharmaceutical Services, Solventum, Baxter International and Cooper Companies.
How can I get Anbio Biotechnology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Anbio Biotechnology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.